HMGB1 induces lung fibroblast to myofibroblast differentiation through NF-κB-mediated TGF-β1 release

QIONG WANG1*, JUN WANG2*, JUNFANG WANG3, SHANCHAO HONG1, FEIFEI HAN1, JINGYU CHEN4 and GUOQIAN CHEN1

1Department of Clinical Laboratory, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023; 2Department of Respiration, Suzhou Kowloon Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu 215000; Departments of 3Orthopedics and 4Thoracic Surgery, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu 214023, P.R. China

Received February 4, 2016; Accepted January 30, 2017

DOI: 10.3892/mmr.2017.6364

Abstract. The proinflammatory factor high-mobility group box protein 1 (HMGB1) has been implicated in the pathogenesis of lung fibrosis; however, the role of HMGB1 in lung fibrosis remains unclear. It has previously been reported that nuclear factor (NF)-κB and transforming growth factor (TGF)-β1 may be involved in lung fibrosis. Therefore, the present study aimed to examine the potential molecular mechanisms that underlie HMGB1-induced lung fibrosis via the regulation of NF-κB and TGF-β1. The results demonstrated that HMGB1 stimulation increased the activation of NF-κB and the release of TGF-β1, as well as the expression of α-smooth muscle actin (α-SMA) and collagen I in human lung fibroblasts in vitro. In addition, inhibition of NF-κB activation blocked HMGB1-induced TGF-β1 release, as well as α-SMA and collagen I expression in lung fibroblasts. Preventing the release of TGF-β1 inhibited HMGB1-induced α-SMA and collagen I expression; however, it had no effect on NF-κB activation. Collectively, these findings indicate that HMGB1 induces fibroblast to myofibroblast differentiation of lung fibroblasts via NF-κB-mediated TGF-β1 release.

Introduction

Lung fibrosis is one of the oldest recorded fibroproliferative disorders, which may ultimately lead to lung failure and mortality (1,2). Several distinct injury-associated or inflammatory causes of interstitial lung disease (ILD) can result in progressive lung scarring (3-7). ILDs that arise with no obvious cause are referred to as idiopathic. Despite the use of anti-inflammatory or immunosuppressive drugs, there is currently no effective treatment for lung fibrosis. Lung transplantation remains the only viable intervention for end-stage lung fibrosis.

Fibrosis is characterized by abnormal fibroblast to myofibroblast differentiation (8-10). Resident pulmonary fibroblasts respond to various stimuli under chronic inflammatory conditions during fibrogenesis. Once activated they differentiate into myofibroblasts, which have a more contractile, proliferative and secretory-active phenotype, and are characterized by the increased expression of α-smooth muscle actin (α-SMA) and extracellular matrix (ECM) components (11,12).

High-mobility group box protein 1 (HMGB1) is a recognized nuclear protein and architectural chromatin-binding factor that binds DNA and promotes protein assembly on specific DNA targets (13,14). However, recent studies have indicated that HMGB1 can be passively released from necrotic cells or actively secreted into the extracellular milieu under appropriate signal stimulation (15,16). Extracellular HMGB1 is a multifunctional cytokine involved in the processes underlying infection, inflammation, apoptosis and immune responses, as well as in tumor development by binding to specific cell-surface receptors (17-20). Notably, numerous studies have indicated that HMGB1 may be involved in fibrotic disorders, including myocardial fibrosis, renal fibrosis and liver fibrosis (21-23).

Pulmonary HMGB1 is markedly upregulated in patients with lung fibrosis and experimental lung fibrosis (24-26). Entezari et al (27) demonstrated that inhibition of HMGB1 may enhance bacterial clearance and protect against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Li et al (28) revealed that HMGB1 mediates the epithelial-to-mesenchymal transition in pulmonary fibrosis, which
involves the transforming growth factor (TGF)-β1/Smad2/3 signaling pathway. However, the role of HMGB1 in lung fibroblast to myofibroblast differentiation remains unclear.

In the present study, the potential role of HMGB1 in fibroblast to myofibroblast differentiation was explored in vitro. Firstly, the effects of HMGB1 on α-SMA expression and ECM production in human lung fibroblasts were detected. Subsequently, the role of TGF-β1 release in HMGB1-induced α-SMA expression and ECM production in human lung fibroblasts was investigated. In addition, the present study explored the potential signaling pathway underlying the regulation of HMGB1-induced fibroblast to myofibroblast differentiation.

Materials and methods

Reagents. Monoclonal antibodies against human α-SMA (catalog no. ab32575) and collagen I (catalog no. ab138492) were purchased from Abcam (Cambridge, UK). Monoclonal antibodies against human β-actin (catalog no. 3700), nuclear factor (NF)-κB-p65 (catalog no. 6956) and phosphorylated (p)-NF-κB-p65 (catalog no. 13346), and horseradish peroxidase (HRP) -conjugated anti-rabbit immunoglobulin (Ig) G (catalog no. 7074) and anti-mouse IgG (catalog no. 7076) secondary antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The enhanced chemiluminescence (ECL) detection system was purchased from Tanon Science and Technology Co., Ltd. (Shanghai, China). Polyvinylidene difluoride (PVDF) membranes were purchased from EMD Millipore (Billerica, MA, USA). Ammonium pyrrolidinedithiocarbamate (PDTC) was purchased from Abcam. TRIZol® reagent was purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). A RevertAid™ First Strand cDNA Synthesis kit was obtained from Fermentas; Thermo Fisher Scientific, Inc. (Pittsburgh, PA, USA). TaqMan® Fast Advanced Master Mix was purchased from Applied Biosystems; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). A human TGF-β1 ELISA kit (catalog no. EK0513) was purchased from Boster (Wuhan, China). Monoclonal antibodies against human TGF-β1 (TGF-β1 neutralization antibody; catalog no. MAB240) and recombinant human HMGB1 Protein, were obtained from R&D Systems, Inc. (Minneapolis, MN, USA). RIPA lysis buffer and a BCA kit were supplied by Thermo Fisher Scientific, Inc. (Waltham, MA, USA). RIPA lysis buffer and a BCA kit were supplied by Thermo Fisher Scientific, Inc. (Waltham, MA, USA). A human TGF-β mediator (catalog no. ab32575) and recombinant human HMGB1 Protein, were obtained from R&D Systems, Inc. (Minneapolis, MN, USA). RIPA lysis buffer and a BCA kit were supplied by Thermo Fisher Scientific, Inc. (Waltham, MA, USA).

Cell culture and treatment. The MRC-5 cells were incubated with 10 µg/ml HMGB1 and the mRNA expression levels of α-SMA and collagen I were detected using RT-qPCR at 0, 3, 6, 12, 24, 36, 48, 72 and 96 h following HMGB1 stimulation, or the phosphorylation levels of NF-κB-p65 were detected by western blotting at 0, 20, 40, 60, 80 min following HMGB1 stimulation. Next, MRC-5 cells were incubated with 10 µg/ml HMGB1 or PBS solvent control, and the protein expression levels of α-SMA and collagen I were detected by western blotting at 72 h following HMGB1 stimulation. In order to inhibit the activation of NF-κB-p65, the PDTC (20 µM) or DMSO solvent control were added into the medium at 30 min prior to addition of HMGB1. In order to block the function of TGF-β1, TGF-β1 neutralization antibody (10 µg/ml) or IgG control (10 µg/ml) were added into the medium with HMGB1.

RNA isolation and RT-qPCR. Total RNA was isolated from the cells using TRIZol® reagent (Thermo Fisher Scientific, Inc.). An equal amount (2 µg) of total RNA was synthesized as first-strand cDNA using the RevertAid™ First Strand cDNA Synthesis kit (Fermentas; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The cDNA was amplified using the TaqMan® Fast Advanced Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) to detect the expression levels of α-SMA, collagen I and β-actin, according to the manufacturer's protocol. Each sample was assayed in triplicate. The thermal cycling conditions were as follows: Initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 sec and annealing at 60°C for 60 sec. The 7500 Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used for all experiments. The relative levels of target gene expression were obtained by calculating the ratio of cycle numbers of the initial exponential amplification phase as determined by the sequence detection system for specific target genes and β-actin using the following formula: 2^(-ΔΔCt) (30,31). The sequences of primers used were as follows: α-SMA forward, 5’-ACTGCGCCATCTCCTACCTC-3’; α-SMA reverse, 5’-ATGGCAACGACACTCCATTCCTC-3’; α-SMA probe 5’-Fam-CCGTCGTCGAGAGACGCCGGCTTCCAGGCAGCACCGGCTG-3’; β-actin forward, 5’-GCCACGACACTTC-3’; β-actin reverse, 5’-GGCCACTGCCTGGATGCGCC-3’; β-actin probe 5’-GCTGGCCGTACAGG-3’; α-actin forward, 5’-GCCACGACACTTC-3’.

Western blot analysis. Cells were lysed using RIPA lysis buffer at 4°C for 30 min and then protein concentration was quantified with a BCA kit according to the manufacturer's protocol. The proteins (50 µg) were subjected to 4-20% PAGE gel electrophoresis (Genscript, Nanjing, Jiangsu, China) and transferred onto PVDF membranes using a Mini-Protean® system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The membranes were incubated for 1 h at room temperature in blocking buffer [5% skim milk in tris-buffered saline plus 0.05% Tween 20 (TBS-T)] prior to overnight incubation with the appropriate antibodies including α-SMA (1:2,000), collagen I (1:3,000), NF-kB p65 (1:1,000) and p-NF-kB p65 (1:1,000) and anti-β-actin (1:1,000) as the internal standard.
at 4˚C. After washing with TBS-T, the membranes were incubated with HRP-conjugated anti-rabbit IgG (1:2,000) and anti-mouse IgG (1:2,000) for 1 h at room temperature. The bands were visualized using the ECL detection system (Tanon Science and Technology Co., Ltd.). The radiographic band density was measured using Quantity One software, version 4.6.2 (Bio-Rad Laboratories, Inc.).

**ELISA.** The levels of TGF-β1 in the cell media were determined using a commercial ELISA kit (Boster Systems, Inc.) according to the manufacturer’s protocol. The optical density at a wavelength of 450 nm was detected by a microplate reader. TGF-β1 concentration was calculated by the standard curve.

**Statistical analysis.** All statistical analyses were performed using the SPSS v.11.5 software (SPSS, Inc., Chicago, IL, USA). The statistical significance of the groups was evaluated by one-way analysis of variance; simultaneous multiple comparisons among groups was conducted using the Bonferroni method. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**HMGB1 induces fibroblast to myofibroblast differentiation in human lung fibroblasts.** Human lung fibroblasts were initially incubated with various doses of HMGB1. After HMGB1 stimulation for 48 h, the expression levels of α-SMA were detected by RT-qPCR. The results demonstrated that HMGB1 increased α-SMA expression in human lung fibroblasts in a dose-dependent manner; the maximal effect was detected following treatment with 10 µg/ml HMGB1 (Fig. 1A). Therefore, 10 µg/ml HMGB1 was chosen for further studies. Human lung fibroblasts were incubated with 10 µg/ml HMGB1, and α-SMA expression was detected at 0, 3, 6, 12, 24, 36, 48, 72 and 96 h using RT-qPCR. The results revealed that α-SMA mRNA expression increased and peaked at 72 h following HMGB1 stimulation (Fig. 1B). In addition, the expression
expression levels of α-SMA and collagen I were markedly increased following HMGB1 stimulation for 72 h (Fig. 1D and E). These results indicated that HMGB1 may induce fibroblast to myofibroblast differentiation of human lung fibroblasts.

**HMGB1 increases TGF-β1 release from human lung fibroblasts.** Human lung fibroblasts were incubated with 10 μg/ml HMGB1, and the protein expression levels of TGF-β1 in the media were detected by ELISA at various time points (0, 3, 6, 12, 24, 36, 48, 72 and 96 h). The results demonstrated that the level of TGF-β1 secretion increased following HMGB1 stimulation, peaked at 6 h and then gradually decreased up to 96 h (Fig. 2). HMGB1-induced TGF-β1 release peaked earlier than HMGB1-induced expression of α-SMA and collagen I in human lung fibroblasts (6 vs. 72 h), thus indicating that TGF-β1 release may mediate HMGB1-induced fibroblast to myofibroblast differentiation of human lung fibroblasts.

**TGF-β1 release is essential for HMGB1-induced fibroblast to myofibroblast differentiation of human lung fibroblasts.** In order to investigate whether TGF-β1 is involved in HMGB1-induced α-SMA expression in human lung fibroblasts, the TGF-β1 neutralization antibody was used to block the function of TGF-β1 during HMGB1 stimulation. Subsequently, the expression levels of α-SMA and collagen I were detected. The results revealed that the TGF-β1 neutralization antibody effectively inhibited HMGB1-induced α-SMA and collagen I expression in human lung fibroblasts (Fig. 3A-D). Collectively, these results indicated that HMGB1 may induce fibroblast to myofibroblast differentiation of human lung fibroblasts via TGF-β1 release.

**NF-κB activation is involved in HMGB1-induced TGF-β1 release and fibroblast to myofibroblast differentiation of lung fibroblasts.** It has previously been reported that NF-κB activation may mediate TGF-β1 release (32). Therefore, the present study initially detected whether HMGB1 could induce NF-κB activation in lung fibroblasts. The results revealed that HMGB1 significantly induced NF-κB activation in lung fibroblasts following HMGB1 stimulation for 60 min (Fig. 4A). Subsequently, the NF-κB inhibitor, PDTC, was used to inhibit NF-κB activation to determine the role of NF-κB activation in HMGB1-induced TGF-β1 release, as well as α-SMA and collagen I expression, in lung fibroblasts. The results demonstrated that the NF-κB inhibitor markedly reduced HMGB1-induced TGF-β1 release (Fig. 4B), as well as α-SMA and collagen I mRNA and protein expression in lung fibroblasts (Fig. 4C-F). Finally, TGF-β1 suppression did not affect HMGB1-induced NF-κB activation in lung fibroblasts (Fig. 4G), suggesting that NF-κB is an upstream regulator of TGF-β1 release in HMGB1-stimulated lung fibroblasts. Collectively, these results indicated that HMGB1 may induce fibroblast to myofibroblast differentiation via NF-κB-mediated TGF-β1 release.

**Discussion**

Lung fibrosis is a common fibroproliferative disorder, which can lead to lung failure and mortality (1,2,33). Despite the use of anti-inflammatory or immunosuppressive drugs,
there is currently no effective treatment for lung fibrosis. Previous studies have revealed that fibroblast to myofibroblast differentiation is pathologically altered during lung fibrosis. Furthermore, it has been suggested that HMGB1 may be associated with lung fibrosis (24-28); however, the role of HMGB1 in lung fibroblast activation and differentiation is unclear. The present study revealed that HMGB1 increased α-SMA and collagen I expression in human lung fibroblasts, indicating that HMGB1 may induce fibroblast to myofibroblast differentiation of lung fibroblasts.

Since TGF-β1 is a key factor that mediates fibroblast to myofibroblast differentiation (34,35), the present study further investigated HMGB1-induced TGF-β1 release from human lung fibroblasts. The results demonstrated that TGF-β1 secretion was significantly increased following HMGB1 stimulation. Notably, HMGB1-induced TGF-β1 release occurred earlier than HMGB1-induced expression of α-SMA and collagen I in human lung fibroblasts (6 vs. 72 h), indicating that TGF-β1 release may mediate HMGB1-induced fibroblast to myofibroblast differentiation of human lung fibroblasts. Further experiments demonstrated that treatment with the TGF-β1 neutralization antibody effectively inhibited HMGB1-induced α-SMA and collagen I expression in human lung fibroblasts. Collectively, these results indicated that HMGB1 may induce fibroblast to myofibroblast differentiation of human lung fibroblasts via TGF-β1 release.

Previous studies have reported that NF-κB activation may mediate TGF-β1 release (36,37). Therefore, the present study determined whether HMGB1 could induce NF-κB activation in lung fibroblasts. The results revealed that HMGB1 significantly induced NF-κB activation in lung fibroblasts. The NF-κB inhibitor, PDTC, was applied to inhibit NF-κB activation in order to...
investigate the role of NF-κB activation in HMGB1-induced TGF-β1 release and fibroblast to myofibroblast differentiation of lung fibroblasts. The results demonstrated that the NF-κB inhibitor markedly reduced HMGB1-induced TGF-β1 release, and α-SMA and collagen I expression in lung fibroblasts. Collectively, the results indicated that HMGB1 may induce fibroblast to myofibroblast differentiation of lung fibroblasts via NF-κB-mediated TGF-β1 release.

It has been reported that HMGB1 accelerates lipopolysaccharide-induced lung fibroblast proliferation in vitro via the NF-κB signaling pathway (38). Conversely, the present study demonstrated that NF-κB activation in lung fibroblasts, induced by HMGB1, may promote TGF-β1 release and induce fibroblast to myofibroblast differentiation. Signal transducer and activator of transcription-3 (STAT-3) has been reported to determine the association between NF-κB and STAT-3 in lung fibroblasts (43). In addition, TGF-β stimulation in vitro leads to Smad2/Smad3-dependent phosphorylation of STAT-3 in lung fibroblasts (39). NF-κB and STAT-3 are involved in fibroblast to myofibroblast differentiation, however, the associations between these two molecules is unclear. Therefore, further investigations are required to determine the association between NF-κB and STAT-3 in the regulation of HMGB1-induced TGF-β1 release and fibroblast to myofibroblast differentiation.

References
1. Górka J, Szczeklik W, Włudarczyk A, Łoboda P, Chmura L and Musial J: Rapidly progressive interstitial lung fibrosis in a patient with myopathic dermatomyositis and anti-MDA5 antibodies. Pol Arch Med Wewn 125: 685-686, 2015.
2. MacKenzie B, Korfei M, Henncke I, Sibinska Z, Tian X, Hezel S, Dilai S, Wasnick R, Schneider B, Wilhelm J, et al: Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respir Res 16: 83, 2015.
3. Curtis JR, Sarsour K, Napalkov P, Costa LA and Schulman KL: Incidence and complications of interstitial lung disease in users of aerosolized recombinant human alfa-1 antitrypsin, abateccept, and anti-tumor necrosis factor α agents, a retrospective cohort study. Arthritis Res Ther 17: 319, 2015.
4. Yamamoto Y, Okamoto I, Otsubo K, Iwama E, Hamada N, Harada T, Takayaka Y and Nakashima Y: Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase (ALK)-positive small cell lung cancer treated with alacticin. Invest New Drugs 33: 1148-1150, 2015.
5. Guo Y, Zhang X, Qin M and Wang X: Changes in peripheral CD14(+)F4/80(+) and CD11b(+) TGF-β1 regulatory B cell populations in rheumatoid arthritis patients with interstitial lung disease. J Thorac Dis 7: 471-477, 2015.
6. Kawaii T, Watanabe N, Yokoyama M, Nakazawa Y, Goto F, Uchiyama T, Higuchi M, Maekawa T, Tamura E, Nagasaka S, et al: Interstitial lung disease with multiple microgranulomas in chronic granulomatous disease. J Clin Immunol 34: 933-940, 2014.
7. Glasser SW, Senft AP, Maxfield MD, Retschilling TL, Baatz JE, Page K and Korthagen TR: Genetic replacement of surfactant protein-C reduces respiratory syncytial virus induced lung injury. Respir Res 14: 19, 2013.
8. Lin L, Wang Y, Liu W and Huang Y: BAMBI inhibits skin fibrosis in keloid through suppressing TGF-β1-induced hypertrophic fibroblast cell proliferation and excessive accumulation of collagen I. Int J Clin Exp Med 8: 13227-13234, 2015.
9. Tsukui T, Ueha S, Shichino S, Inagaki Y and Matsushima K: Intratracheal cell transfer demonstrates the profibrotic potential of resident fibroblasts in pulmonary fibrosis. Am J Pathol 185: 2939-2948, 2015.
10. Geng J, Huang X, Li Y, Xu X, Li S, Jiang D, Liang J, Jiang D, Wang C and Dai H: Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis. Respir Res 16: 124, 2015.
11. Ma X, Yang F, Yang S, Rasul A, Li T, Liu L, Kong M, Guo D and Ma T: Number and distribution of myofibroblasts and α-smooth muscle actin expression levels in fetal membranes with and without gestational complications. Mol Med Rep 12: 2784-2792, 2015.
12. Jung YS, Liu XW, Chirico R, Warner RB, Fridman R and Kim HR: TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS One 7: e38773, 2012.
13. Watson M, Storti K, Fischl H, Cato L and Thomas JQ: Characterization of the interaction between HMGB1 and H3-a possible means of positioning HMGB1 in chromatin. Nucleic Acids Res 42: 848-859, 2014.
14. Little AJ, Corbett E and Schatz DG: Cooperative recruitment of HMGB1 during V(DJ) recombination through interactions with RAG1 and DNA. Nucleic Acids Res 41: 3289-3301, 2013.
15. Zhao T, Ren H, Wang X, Liu P, Yan F, Jiang W, Li Y, Li J, Gribben JG, Jia L and Hao H: Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget 6: 27816-27831, 2015.
16. Jiang G, Wang Y, Yun J, Hajrassouliha AR, Zhao Y, Sun D, Kaplan HJ and Shao H: HMGB1 release triggered by the interaction of live retinal cells and uveotogenic T cells is Fas/FasL activation-dependent. J Neuroinflammation 12: 179, 2015.
17. Tabata C, Kanemura S, Tabata E, Shibata E, Otsuki T, Nishizaki T and Nakano T: Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 47: 684-688, 2013.
18. Laws TR, Clark GC and DElia RV: Immune profiling of the progression of a BALB/c mouse aerosol infection by Burkholderia pseudomallei and the therapeutic implications of targeting HMGB1. Int J Infect Dis 40: 1-8, 2015.
19. Qi L, Sun X, Li FE, Zhu BS, Braun FK, Liu ZQ, Tang JL, Wu C, Xu F, Wang HH, et al: HMGB1 promotes mitochondrial dysfunction-triggered striatal neurodegeneration via autophagy and apoptosis activation. PLoS One 10: e0142901, 2015.
20. Parodi M, Pedrazzini M, Cantoni C, Averna M, Patrone M, Cavaletto M, Spertino S, Pende D, Balsamo M, Pietra G, et al: Natural killer (NK)/melanoma cell interaction induces HMGB1 mediated release of proinflammatory high mobility group box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncoimmunology 4: e1052353, 2015.
21. Wang FP, Li L, Li J, Wang YJ, Wang LY and Jiang W: High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PLoS One 9: e94573, 2014.
22. Zhang W, Lavine KJ, Epelman S, Evans SA, Weinerheim CJ, Barger PM and Mann DL: Necrotic myofibroblasts release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myofibroblast inflammation and fibrosis in vivo. J Am Heart Assoc 4: e00093, 2015.
23. Zhang M, Guo Y, Fu H, Hu S, Pan J, Wang Y, Cheng J, Song J, Yu Q, Zhang S, et al: Chop deficiency prevents UUO-induced renal fibrosis by attenuating fibrotic signals originated from HMGB1/TLR4/NFκB/IL-1β signaling. Cell Death Dis 6: e1847, 2015.
24. Ebina M, Taniguchi H, Miyasho T, Yamada S, Shibata N, Ohta H, Hisata S, Ohkouchi S, Tamada T, Nishimura H, et al: Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis. Pulm Med 2011: 916486.
25. Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J, Ono Y, Yamada M, Yamada S, Kawanou K and Nakashima Y: The role of high mobility group box 1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 39: 440-447, 2008.
26. Tiringer K, Treis A, Kanozler S, Witt C, Ghanim B, Gruber S, Schmidtaher K, Renner S, Dehlinc E, Nachbaur E, et al: Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients. Eur Respir J 44: 802-805, 2014.
27. Entezari M, Weiss DJ, Sitapara R, Whittaker L, Wargo MJ, Li J, Wang H, Yang H, Sharma L, Phan BD, et al: Inhibition of high-mobility group box 1 (HMGB1) abrogates bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med 18: 477-485, 2012.
28. Li GC, Li DL, Xu L, Mo XT, Cui WH, Zhao P, Zhou WC, Gao J and Li J: High-mobility group box 1 mediates epitelial-to-mesenchymal transition in pulmonary fibrosis involving transforming growth factor-β1/Smad2/3 signaling. J Pharmacol Exp Ther 354: 302-309, 2015.
29. Yang Z, Sun Z, Liu H, Ren Y, Shao D, Zhang W, Lin J, Wolfram J, Wang F and Nie S: Connective tissue growth factor stimulates the proliferation, migration and differentiation of lung fibroblasts during paraquat-induced pulmonary fibrosis. Mol Med Rep 12: 1091-1097, 2015.

30. Hou F, Wang L, Wang H, Gu J, Li M, Zhang J, Ling X, Gao X and Luo C: Elevated gene expression of S100A12 is correlated with the predominant clinical inflammatory factors in patients with bacterial pneumonia. Mol Med Rep 11: 4345-4352, 2015.

31. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.

32. Di JM, Pang J, Pu XY, Zhang Y, Liu XP, Fang YQ, Ruan XX and Gao X: Toll-like receptor 9 agonists promote IL-8 and TGF-beta production via activation of nuclear factor kappaB in PC-3 cells. Cancer Genet Cytogenet 192: 60-67, 2009.

33. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.

34. Ji H, Tang H, Lin H, Mao J, Gao L, Liu J and Wu T: Rho/Rock cross-talks with transforming growth factor-beta/Smad pathway participates in lung fibroblast-myofibroblast differentiation. Biomed Rep 2: 787-792, 2014.

35. Sassoli C, Chellini F, Pini A, Tani A, Nistri S, Nosi D, Zecchi-Orlandini S, Bani D and Formigli L: Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β1/Smad3 signaling. PLoS One 8: e63896, 2013.

36. Song J, Zhu Y, Li J, Liu J, Gao Y, Ha T, Que L, Liu L, Zhu G, Chen Q, et al: Pellinol-mediated TGF-β1 synthesis contributes to mechanical stress induced cardiac fibroblast activation. J Mol Cell Cardiol 79: 145-156, 2015.

37. Bizzarro V, Fontanella B, Carratù A, Belvedere R, Marfella R, Parente L and Petrella A: Annexin A1 N-terminal derived peptide Ac2-26 stimulates fibroblast migration in high glucose conditions. PLoS One 8: e45639, 2012.

38. Li W, Xu Q, Deng Y, Yang Z, Xing S, Zhao X, Zhu P, Wang X, He Z and Gao Y: High-mobility group box 1 accelerates lipopolysaccharide-induced lung fibroblast proliferation in vitro: involvement of the NF-xB signaling pathway. Lab Invest 95. 635-647, 2015.

39. Pedroza M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, Blackburn MR, Tweardy DJ and Agarwal SK: STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB J 30: 129-140, 2016.